首页> 外国专利> CHIMERIC ANTIBODY THAT BINDS WITH HUMAN CD40 (VARIANTS), NUCLEIC ACID MOLECULE (VARIANTS), EXPRESSION VECTOR (VARIANTS), HUMANIZED ANTIBODY (VARIANTS), PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASE MEDIATED BY T-CELLS (VARIANTS), METHOD FOR TREATMENT OF PATIENT WITH DISEASES MEDIATED BY T-CELLS (VARIANTS)

CHIMERIC ANTIBODY THAT BINDS WITH HUMAN CD40 (VARIANTS), NUCLEIC ACID MOLECULE (VARIANTS), EXPRESSION VECTOR (VARIANTS), HUMANIZED ANTIBODY (VARIANTS), PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASE MEDIATED BY T-CELLS (VARIANTS), METHOD FOR TREATMENT OF PATIENT WITH DISEASES MEDIATED BY T-CELLS (VARIANTS)

机译:与人类CD40结合的嵌合抗体(变体),核酸分子(变体),表达载体(变体),人源化抗体(变体),用于治疗T细胞病(变体)的疾病的药物组合物(变体) T细胞介导的疾病(变种)

摘要

FIELD: molecular biology, medicine, pharmacy. SUBSTANCE: invention relates to new chimeric and humanized antibodies showing specificity to human CD40 that block interaction between gp39 and CD40. Proposed antibodies raised for CD40 are effective in modulating humoral immune response to antigens depending on T-cells in case of collagen-induced arthritis, in prevention for rejection of skin transplants. Indicated antibodies can be useful owing to their anti-inflammatory properties in pharmaceutical composition and method for treatment of disease mediated by T-cells. EFFECT: valuable biological and medicinal properties of antibody, enhanced effectiveness of treatment. 27 cl, 4 tbl, 33 dwg, 5 ex
机译:领域:分子生物学,医学,药学。物质:本发明涉及对人CD40表现出特异性的新型嵌合抗体和人源化抗体,该抗体阻断gp39和CD40之间的相互作用。在胶原诱导的关节炎的情况下,针对CD40提出的拟议抗体可有效调节针对T细胞的针对抗原的体液免疫反应,从而预防皮肤移植排斥反应。所指示的抗体由于其在药物组合物和用于治疗由T细胞介导的疾病的方法中的抗炎性质而有用。效果:抗体的宝贵生物学和医学特性,增强了治疗效果。 27厘升,4汤匙,33载重吨,5前

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号